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Ciprandi et al.1 have made a credible attempt in
their measurement of bronchial hyperresponsive-
ness (BHR) in patients with allergic rhinitis (AR). A
number of important points however have to be
raised regarding their methodology and possible
pharmacological intervention in such patients.
In their assessment of non-specific BHR to
methacholine, the authors have made only an
arbitrary stratification regarding the extent of
BHR, without offering any justification for doing
so. The American Thoracic Society has adopted a
means of stratifying the degree of BHR according to
the concentration of methacholine required to
produce a 20% fall in forced expiratory volume in
1 s—the PC20 threshold.
2 For example, normal BHR
is considered present when the PC20 is416mg/ml,
while borderline, mild, and moderate-to-severe
BHR is present when values are 4.0–1.6, 1.0–4.0
and o1mg/ml, respectively. Moreover, BHR to
methacholine is poorly associated with inflamma-
tory cell infiltrate, while BHR to adenosine mono-
phosphate (AMP) is a far superior surrogate marker
of underlying inflammation and has a closer
association to allergic airway inflammation than
the use of direct bronchoconstrictor such as
methacholine.3 Using an indirect bronchoconstric-
tor stimulus such as AMP in the present study would
therefore have provided further information re-
garding the extent of endobronchial inflammation
in conjunction with airway lability.
Guidelines have been developed which suggest
that AR is classified as being intermittent or
persistent in nature, and subsequently graded
according to whether symptoms are mild, moder-
ate or severe.4 The authors refer to AR as being
perennial or seasonal in nature, and have therefore
not taken into account changes in classification
which can allow a more robust approach to
epidemiological and pathophysiological under-
standing, diagnosis and treatment.
In the present study, over 50% of patients with AR
did in fact demonstrate some degree of BHR toee front matter & 2005 Elsevier Ltd. All rights reserv
med.2005.03.009methacholine.1 This in turn suggests that in addition
to allergen avoidance, a co-ordinated approach to
treatment of the unified airway may be required,
especially as many as 40% of patients with AR have
asthma.5 Current evidence suggests that intranasal
corticosteroids should be the first line treatment in
patients with AR.4 However, mediator blockade with a
leukotriene CysLT1-receptor antagonist and a hista-
mine H1-receptor antagonist provides advantages of
efficacy following single doses, a quick onset of action
and beneficial effects upon BHR and airway calibre in
patients with AR and concomitant asthma.6,7References
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